Product overview

GSK’s underlying growth in 2004 was driven by the strong performance of our key products

Total turnover

£20.3bn
turnover grew 1%, despite the loss of £1.5 billion of sales to generics

Consumer Healthcare
turnover £3.2 bn,
grew 3%

Pharmaceuticals
turnover £17.1 bn,
grew 1%

Piechart: 16% Consumer Healthcare and 84% Pharmaceutical

KEY PHARMACEUTICAL PRODUCTS

£6.5 bn
turnover of five key products and vaccines grew by 22%

Seretide/Advair
£2,461m
grew 19%
GSK's largest selling product for asthma and chronic obstructive pulmonary disease (COPD) is the sixth largest pharmaceutical product globally and the second largest in Europe. Avandamet

Valtrex
£571m
grew 24%
Strong growth has been driven by the genital herpes medication in the US.

Avandia/Avandamet £1,116m
grew 32%
GSK’s diabetes treatment continues to perform strongly.

Coreg
£432m
grew 34%
Continues to benefit from its wide range of indications in heart disease.

Lamictal
£678m
grew 32%
Indicated for epilepsy and bipolar disorder Lamictal continues to grow strongly.

VACCINES

£1,196m
GSK’s vaccines business had a strong year, with sales up 11%.

Infanrix/Pediarix
grew 12% to £357 million

Fluarix
grew 38% to £79 million

Priorix
grew 14% to £95 million

CONSUMER HEALTHCARE

£3.2 bn
GSK’s Consumer Healthcare
business grew 3%.

Top 5 Consumer Healthcare products
(total turnover)

1	Nicotine replacement therapy	£341m
2	Aquafresh	£329m
3	Lucozade	£268m
4	Sensodyne	£213m
5	Panadol	£208m

Over-the-counter
grew 2% to £1,489 million

Nutritional healthcare
grew 5% to £636 million

Oral healthcare
grew 4% to £1,088 million

NiQuitinCQ, Lucozade and AquaFresh

12 GSK products achieved sales of more than £500 million in 2004

1	Seretide/Advair	£2,461m
2	Avandia/Avandamet	£1,116m
3	Seroxat/Paxil	£1,063m
4	Zofran	£763m
5	Wellbutrin	£751m
6	Augmentin	£708m

7	Imigran/Imitrex	£682m
8	Lamictal	£678m
9	Flixotide/Flovent	£618m
10	Flixonase/Flonase	£578m
11	Valtrex	£571m
12	Combivir	£571m


	Previous
	Next

Topˆ